共 60 条
[1]
Papadakis KA(2000)Role of cytokines in the pathogenesis of inflammatory bowel disease Annu Rev Med 51 289-298
[2]
Targan SR(2015)Biologics in inflammatory bowel disease: what are the data? U Eur Gastroenterol J 3 419-428
[3]
Côté-Daigneault J(2008)Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 244-279
[4]
Bouin M(2009)Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data Aliment Pharmacol Ther 30 265-274
[5]
Lahaie R(2012)Saving money in the European healthcare systems with biosimilars GaBI J 1 120-126
[6]
Colombel J-F(2014)Physicochemical characterization of Remsima MAbs 6 1163-1177
[7]
Poitras P(2013)A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study Ann Rheum Dis 72 1613-1620
[8]
Tracey D(2013)A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study Ann Rheum Dis 72 1605-1612
[9]
Klareskog L(2005)Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology Can J Gastroenterol 19 5-36
[10]
Sasso EH(2006)Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index Inflamm Bowel Dis 12 304-310